215 related articles for article (PubMed ID: 16337994)
41. Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer.
Chetrit A; Hirsh-Yechezkel G; Ben-David Y; Lubin F; Friedman E; Sadetzki S
J Clin Oncol; 2008 Jan; 26(1):20-5. PubMed ID: 18165636
[TBL] [Abstract][Full Text] [Related]
42. A candidate precursor to serous carcinoma that originates in the distal fallopian tube.
Lee Y; Miron A; Drapkin R; Nucci MR; Medeiros F; Saleemuddin A; Garber J; Birch C; Mou H; Gordon RW; Cramer DW; McKeon FD; Crum CP
J Pathol; 2007 Jan; 211(1):26-35. PubMed ID: 17117391
[TBL] [Abstract][Full Text] [Related]
43. A new germline mutation in BRCA1 gene in a sicilian family with ovarian cancer.
Calò V; Agnese V; Gargano G; Corsale S; Gregorio V; Cascio S; Cammareri P; Bruno L; Augello C; Gullo A; Sisto PS; Badalamenti G; Valerio MR; Napoli L; Gebbia N; Bazan V; Russo A
Breast Cancer Res Treat; 2006 Mar; 96(1):97-100. PubMed ID: 16244786
[TBL] [Abstract][Full Text] [Related]
44. Germline mutations of TP53 and BRCA2 genes in breast cancer/sarcoma families.
Manoukian S; Peissel B; Pensotti V; Barile M; Cortesi L; Stacchiotti S; Terenziani M; Barbera F; Pasquini G; Frigerio S; Pierotti MA; Radice P; Della-Torre G
Eur J Cancer; 2007 Feb; 43(3):601-6. PubMed ID: 17224268
[TBL] [Abstract][Full Text] [Related]
45. [Both somatic and germline genetics of the TP53-pathway influence ovarian cancer incidence and survival].
Böhnke A; Jung J; Taubert H; Hauptmann S; Bartel F
Verh Dtsch Ges Pathol; 2007; 91():233-42. PubMed ID: 18314620
[TBL] [Abstract][Full Text] [Related]
46. Mutation analysis of BRCA1 and BRCA2 from 793 Korean patients with sporadic breast cancer.
Han SH; Lee KR; Lee DG; Kim BY; Lee KE; Chung WS
Clin Genet; 2006 Dec; 70(6):496-501. PubMed ID: 17100994
[TBL] [Abstract][Full Text] [Related]
47. Germline copy number variations in BRCA1-associated ovarian cancer patients.
Yoshihara K; Tajima A; Adachi S; Quan J; Sekine M; Kase H; Yahata T; Inoue I; Tanaka K
Genes Chromosomes Cancer; 2011 Mar; 50(3):167-77. PubMed ID: 21213370
[TBL] [Abstract][Full Text] [Related]
48. Mutation analysis of BRCA1, TP53, and KRAS2 in ovarian and related pelvic tumors.
Tworek H; Peng R; Fetzer S; Werness BA; Piver MS; Allen HJ; DiCioccio RA
Cancer Genet Cytogenet; 1999 Jul; 112(2):105-18. PubMed ID: 10686936
[TBL] [Abstract][Full Text] [Related]
49. BRCA1 genetic testing in 106 breast and ovarian cancer families from Southern Italy (Sicily): a mutation analyses.
Russo A; Calò V; Agnese V; Bruno L; Corsale S; Augello C; Gargano G; Barbera F; Cascio S; Intrivici C; Rinaldi G; Gulotta G; Macaluso M; Surmacz E; Giordano A; Gebbia N; Bazan V
Breast Cancer Res Treat; 2007 Nov; 105(3):267-76. PubMed ID: 17221156
[TBL] [Abstract][Full Text] [Related]
50. Mutation screening of the BRCA1 gene in sporadic breast cancer in southern Chinese populations.
Haitian Z; Yunfei L; Jian Z; Jian L; Qinghua L; Fuqiang W
Breast; 2008 Dec; 17(6):563-7. PubMed ID: 18835712
[TBL] [Abstract][Full Text] [Related]
51. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
[TBL] [Abstract][Full Text] [Related]
52. The role of p53 mutation in BRCA1-associated ovarian cancer.
Rose SL; Buller RE
Minerva Ginecol; 2002 Jun; 54(3):201-9. PubMed ID: 12063435
[TBL] [Abstract][Full Text] [Related]
53. Somatic TP53 mutations are relatively rare among adrenocortical cancers with the frequent 17p13 loss of heterozygosity.
Libè R; Groussin L; Tissier F; Elie C; René-Corail F; Fratticci A; Jullian E; Beck-Peccoz P; Bertagna X; Gicquel C; Bertherat J
Clin Cancer Res; 2007 Feb; 13(3):844-50. PubMed ID: 17289876
[TBL] [Abstract][Full Text] [Related]
54. Familial clustering of site-specific cancer risks associated with BRCA1 and BRCA2 mutations in the Ashkenazi Jewish population.
Simchoni S; Friedman E; Kaufman B; Gershoni-Baruch R; Orr-Urtreger A; Kedar-Barnes I; Shiri-Sverdlov R; Dagan E; Tsabari S; Shohat M; Catane R; King MC; Lahad A; Levy-Lahad E
Proc Natl Acad Sci U S A; 2006 Mar; 103(10):3770-4. PubMed ID: 16537453
[TBL] [Abstract][Full Text] [Related]
55. TP53 gene mutations of lung cancer patients in upper northern Thailand and environmental risk factors.
Bumroongkit K; Rannala B; Traisathit P; Srikummool M; Wongchai Y; Kangwanpong D
Cancer Genet Cytogenet; 2008 Aug; 185(1):20-7. PubMed ID: 18656689
[TBL] [Abstract][Full Text] [Related]
56. High proportion of BRCA1/2 founder mutations in Hispanic breast/ovarian cancer families from Colombia.
Torres D; Rashid MU; Gil F; Umana A; Ramelli G; Robledo JF; Tawil M; Torregrosa L; Briceno I; Hamann U
Breast Cancer Res Treat; 2007 Jun; 103(2):225-32. PubMed ID: 17080309
[TBL] [Abstract][Full Text] [Related]
57. Sporadic epithelial ovarian cancer: clinical relevance of BRCA1 inhibition in the DNA damage and repair pathway.
Weberpals JI; Clark-Knowles KV; Vanderhyden BC
J Clin Oncol; 2008 Jul; 26(19):3259-67. PubMed ID: 18591560
[TBL] [Abstract][Full Text] [Related]
58. TP53 and ovarian cancer.
Schuijer M; Berns EM
Hum Mutat; 2003 Mar; 21(3):285-91. PubMed ID: 12619114
[TBL] [Abstract][Full Text] [Related]
59. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada.
Risch HA; McLaughlin JR; Cole DE; Rosen B; Bradley L; Fan I; Tang J; Li S; Zhang S; Shaw PA; Narod SA
J Natl Cancer Inst; 2006 Dec; 98(23):1694-706. PubMed ID: 17148771
[TBL] [Abstract][Full Text] [Related]
60. Ashkenazi founder BRCA1/BRCA2 mutations in Slovak hereditary breast and/or ovarian cancer families.
Cierniková S; Tomka M; Kovác M; Stevurková V; Zajac V
Neoplasma; 2006; 53(2):97-102. PubMed ID: 16575464
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
